Gina Mauro | Authors


Neratinib Plus Capecitabine Improved PFS in Patients With HER2+ Breast Cancer With Brain Mets

December 15, 2020

Neratinib in combination with capecitabine induced a 34% reduction in the risk of disease progression or death as treatment of patients with HER2-positive breast cancer who had central nervous system metastases at baseline compared with lapatinib and capecitabine.

Higher Dosing Schedules of Panobinostat Plus Subcutaneous Bortezomib Triplet Appears Promising in Relapsed/Refractory Myeloma

December 07, 2020

A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.

Kaelin Speaks to the Future of I/O, HIF-2α, CDK4/6 Inhibitors in VHL Disease–Associated RCC

November 07, 2020

During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.

Selecting I/O or Targeted Therapy as Adjuvant Treatment of BRAF-Mutant Melanoma

November 05, 2020

During a virtual presentation for the 38th Annual Chemotherapy Foundation Symposium, Janice M. Mehnert, MD explained the science behind selecting the optimal adjuvant therapy for patients with BRAF-mutant melanoma. The options Mehnert weighed were immunotherapy and BRAF-targeted therapy.